Published TCIMAIL newest issue No.198
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 288383-20-0 | Product Number: C3918
Cediranib
×
![]()
×
Purity: >95.0%(T)(HPLC)
Synonyms:
- AZD 2171
- 4-[(4-Fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline
Product Documents:
| Size | Unit Price | Belgium | Japan* | Quantity |
|---|---|---|---|---|
| 5MG |
€65.00
|
Contact Us | 36 |
|
*Stock available in Belgium will be delivered in 1 to 3 days
*Stock available in Japan will be delivered in 1 to 2 weeks (excludes regulated items and dry ice shipments).
| Product Number | C3918 |
| Purity / Analysis Method | >95.0%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__2__5H__2__7FN__4O__3 = 450.51 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Refrigerated (0-10°C) |
| Store Under Inert Gas | Store under inert gas |
| Condition to Avoid | Air Sensitive,Heat Sensitive |
| CAS RN | 288383-20-0 |
| Reaxys Registry Number | 11404252 |
| MDL Number | MFCD09954115 |
Specifications
| Appearance | White to Light yellow powder to crystal |
| Purity(HPLC) | min. 95.0 area% |
| Purity(Nonaqueous Titration) | min. 95.0 % |
| NMR | confirm to structure |
Properties (reference)
| Maximum Absorption Wavelength | 530 nm (MeOH) |
GHS
Related Laws:
| RTECS# | VA1424500 |
Transport Information:
| HS Number | 2933599590 |
Application
Cediranib: A VEGF Receptor Tyrosine Kinase Inhibitor
Receptors for VEGF (vascular endothelial growth factor-A) play a central role in vasculogenesis and angiogenesis and are therefore targets for cancer therapy. Cediranib (AZD2171) and its water-soluble maleate [R0277] are VEGF receptor tyrosine kinase inhibitors used in cancer research. (The product is for research use only.)
References
- AZD2171 : A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer
- The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies (a review)
- Cediranib , a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer
- Solubility and stability of cediranib maleate
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.